R
Ross C. Donehower
Researcher at Johns Hopkins University
Publications - 233
Citations - 32588
Ross C. Donehower is an academic researcher from Johns Hopkins University. The author has contributed to research in topics: Pharmacokinetics & Chemotherapy. The author has an hindex of 72, co-authored 229 publications receiving 28457 citations. Previous affiliations of Ross C. Donehower include Johns Hopkins University School of Medicine & National Institutes of Health.
Papers
More filters
Journal ArticleDOI
Clinical and Pharmacologic Reappraisal of Dichloromethotrexate
Alexander Hantel,Eric K. Rowinsky,Dennis A. Noe,William P. McGuire,Louise B. Grochow,Barbara L. Vito,David S. Ettinger,Ross C. Donehower +7 more
TL;DR: DCMTX's primarily nonrenal elimination suggests that it may have an advantage over methotrexate when combined with nephrotoxic drugs such as cisplatin, but there is little reason to commit major resources to further evaluation of DCMTX unless significant advantages in antineoplastic activity are identified.
Journal ArticleDOI
A phase 1b/2 study of INCB039110 + nab-paclitaxel (N) and gemcitabine (G) in patients (pts) with advanced solid tumors and pancreatic cancer (PC).
Gregory L. Beatty,Safi Shahda,J. Thaddeus Beck,Nikhil Uppal,Steven J. Cohen,Ross C. Donehower,A. Eli Gabayan,Albert Assad,Julie Switzky,Hui-Ling Zhen,Daniel D. Von Hoff +10 more
TL;DR: The primary objective was to evaluate safety/tolerability in this phase 1b/2 open-label study evaluating INCB039110 in combination with N and G in pts with advanced or metastatic solid tumors and patients who had not received prior chemotherapy.
Journal ArticleDOI
Incidence and prognostic impact of KRAS and BRAF mutations in patients undergoing liver surgery for colorectal metastases.
Georgios Karagkounis,Michael Torbenson,Hubert D. Daniel,Nilofer S. Azad,Luis A. Diaz,Ross C. Donehower,Kenzo Hirose,Timothy M. Pawlik,Michael A. Choti +8 more
TL;DR: A large number of patients with colorectal cancer metastases and KRAS and BRAF metastases are diagnosed with at least one type of cancer, and the prognostic determinants of these diseases can be determined through molecular biomarkers.
Journal ArticleDOI
Phase I study of continuous weekly dosing of dimethylamino benzoylphenylurea (BPU) in patients with solid tumours.
Wells A. Messersmith,Michelle A. Rudek,Sharyn D. Baker,Ming Zhao,Connie Collins,A. Dimitrios Colevas,Ross C. Donehower,Michael A. Carducci,Antonio C. Wolff +8 more
TL;DR: A long half-life and accumulation of BPU and active metabolites were observed, recommending against a continuous administration, and weekly oral BPU therapy should be further tested using an interrupted schedule.
Journal ArticleDOI
Phase II trial of menogaril as initial chemotherapy for metastatic breast cancer.
M. John Kennedy,Ross C. Donehower,Louise B. Grochow,David S. Ettinger,John H. Fetting,Martin D. Abeloff +5 more
TL;DR: Eighteen women with metastatic breast cancer previously untreated with chemotherapy were entered on a phase II trial of intravenous menogaril, a new anthracycline derivative, which has modest activity as first line therapy but also has significant marrow and local toxicity.